ABPRO
Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently... and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.
ABPRO
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2007-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.abpro.com
Total Employee:
11+
Status:
Active
Contact:
(800) 396-5890
Email Addresses:
[email protected]
Total Funding:
42.39 M USD
Technology used in webpage:
SPF IPv6 Google Apps For Business Google WordPress 6.0 Choopa PointDNS
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
OnCirc Diagnostics
OnCirc Diagnostics is a biotechnology company involved in the in vivo diagnostics of circulating tumor cells.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Employees Featured
Founder
Official Site Inspections
http://www.abpro.com Semrush global rank: 3.05 M Semrush visits lastest month: 5.29 K
- Host name: 195.35.60.122
- IP address: 195.35.60.122
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Abpro"
Abpro - Crunchbase Company Profile & Funding
Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial …See details»
Abpro Corporation
Abpro.com. Site will be available soon. Thank you for your patience! User Login ...See details»
Next-Generation Antibody Therapeutics - Abpro …
Jan 22, 2024 Abpro offers attractive compensation packages and comprehensive benefits, fostering a culture where employees can develop and thrive. We’re searching for individuals brimming with enthusiasm, passion, and …See details»
Abpro Corporation - Investor Relations
Jan 22, 2025 Abpro Corporation is a biotechnology company located in Woburn, Massachusetts. The company’s mission is to improve the lives of mankind facing severe and life-threatening …See details»
Abpro - LinkedIn
Abpro | 5,258 followers on LinkedIn. Developing antibody therapies to improve the lives of patients facing severe and life-threatening diseases. | We're a public biotech company …See details»
Governance Overview - Abpro Corporation
Learn more about Abpro Corporation's corporate governance and view the company's governance documents and committee charters.See details»
Abpro - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Abpro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Contacts 28. ... Abpro …See details»
Chan Brothers Create Abpro To Speed Pace Of …
Jan 11, 2023 That mission led to the founding of two bio technology firms, the latest of which is Abpro.The Woburn, Massachusetts-based company was founded in 2007, with Ian Chan serving as CEO and Eugene Chan ...See details»
Abpro Corp. (Abpro Corp.) - 药物管线_专利_临床试验_投融营收_最 …
Abpro to receive equity investment and potential milestones up to $1.75B Partnership combines Abpro’s Diversimmune™ and Multimab™ platform with Celltrion’s leadership in worldwide …See details»
News Releases - Abpro Corporation
Jan 22, 2024 Abpro Announces Closing of Business Combination with Atlantic Coastal Acquisition Corp. II January 22, 2024 Abpro Announces Filing of Registration Statement on …See details»
Abpro Holdings, Inc. Announces Departure of CEO Ian Chan and
Mar 10, 2025 Abpro Holdings, Inc., a biotechnology company focused on developing antibody therapies for severe diseases, has announced the departure of CEO Ian Chan. Miles Suk, the …See details»
Abpro Announces Closing of Business Combination with Atlantic …
Nov 14, 2024 Abpro Corporation, a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody …See details»
Abpro Announces Closing of Business Combination with
Nov 14, 2024 Abpro Expected to Begin Trading on Nasdaq on Wednesday, November 13, 2024 Under the Tickers “ABP” and “ABPWW” ; WOBURN, Mass. and NEW YORK, Nov. 13, 2024 …See details»
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO
Sep 22, 2023 Abpro began a phase 2/3 clinical trial of its lead COVID-19 candidate, ABP-300, late in 2020. One year later, the biotech touted the effect of its follow-up candidate, ABP-310, …See details»
Abpro Statement on the Departure of Former CEO Ian Chan
Mar 10, 2025 Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, ranked top 25 in the world by market capitalization, in an exclusive collaboration to …See details»
Abpro Corporation initiated with a Buy at Maxim
Feb 24, 2025 Maxim initiated coverage of Abpro Corporation with a Buy rating and $4 price target The company leverages its DiversImmune and MultiMab discovery and engineering …See details»
Abpro Holdings Completes Merger and Raises $10 Million
Dec 12, 2024 Abpro Holdings is a biotechnology company based in Woburn, Massachusetts, focused on developing next-generation antibody therapies to treat severe and life-threatening …See details»
An Update on Abpro's HER2/CD3 T cell Engager - pharmexec.com
Feb 18, 2025 In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro gives an update on the preclinical development of Abpro's lead HER2/CD3 T cell …See details»
Abpro Holdings Completes Merger and Raises $10 Million
Dec 12, 2024 Abpro Holdings is a biotechnology company based in Woburn, Massachusetts, focused on developing next-generation antibody therapies to treat severe and life-threatening …See details»
ABP-102(Abpro) - Drug Targets, Indications, Patents - Synapse
Abpro Expected to Begin Trading on Nasdaq on Wednesday, November 13, 2024 Under the Tickers "ABP" and "ABPWW" WOBURN, Mass. and NEW YORK, Nov. 13, 2024 …See details»